Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies

BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, ...
Zacks Investment Research on MSN

NTLA stock up more than 6% as FDA lifts ATTRv-PN study clinical hold

Intellia Therapeutics NTLA announced that the FDA lifted the clinical hold on the investigational new drug application (IND) ...
Ophthalmology Times

FDA clears Novaliq’s Investigational New Drug application for NOV05

The US Food and Drug Administration (FDA) has cleared Novaliq’s Investigational New Drug (IND) application for NOV05, enabling the initiation of the EYETAC phase II clinical trial ( NCT07285070) in ...
The Manila Times

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease

Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - ...
Healio

FDA accepts IND for synthetic psilocybin therapeutic to treat PTSD

The FDA has accepted an investigational new drug application from a global biotechnology company for its investigational, ...

FDA Approves IND for Hallux Subungual Gel 42%

A New Approach Enabling Physicians to Treat Toenail Fungus at the Point-of-Care HSG 42 is highly differentiated. It is ...

Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), today announced that ISM8969, an orally available NLRP3 ...
News-Medical.Net on MSN

AI-designed NLRP3 inhibitor receives FDA clearance for Parkinson disease trials

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial ...
Targeted Oncology

FDA Clears IND for Phase 3 Trial of iSCIB1+ in Advanced Melanoma

The FDA cleared the investigational new drug (IND) application for a global phase 3 registrational trial of iSCIB1 +, a DNA plasmid vaccine, in patients with advanced melanoma, scheduled to commence ...

Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted ...
JD Supra

Let It Grow: FDA Revises Q&A Guidance to Support Sponsors With the Implementation of Expanded Access Programs

“Let it grow, let it blossom,” said Eric Clapton, and so the Food and Drug Administration expects of expanded access programs with the issuance of its guidance on “Expanded Access to Investigational ...